8-K filing — Aclaris Therapeutics, Inc. (ACRS)
Filed: 2026-10-27 AccNo: 0001104659-26-119231 Size: 688 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Aclaris Therapeutics Reports Positive Phase 1b Proof-of-Concept Results for ATI-052
Aclaris Therapeutics announced positive primary analysis results from its Phase 1b proof-of-concept trial of ATI-052, a bispecific antibody targeting TSLP and IL-4Rα, in patients with atopic dermatitis and asthma.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Aclaris Says Early Data Validates Dual-Target Approach for Eczema, Asthma Drug
Aclaris Therapeutics announces positive Phase 1b trial data for ATI-052 in eczema and asthma alongside a $50 million public financing round.
Aclaris Therapeutics Prices $50 Million Public Offering
Aclaris Therapeutics announced the pricing of an underwritten public offering of common stock and pre-funded warrants expected to generate approximately $50 million in gross proceeds.